Patrick Coffee is a reporter for The Wall Street Journal's CMO Today in New York, where he covers marketing and advertising. He was previously a correspondent at Business Insider, covering ...

Editas Medicine ends development of its gene-editing therapy for thalassaemia and sickle cell, shedding 65% of staff and narrowing its R&D focus.